InflaRx shares surge 86.99% premarket after positive Phase 2a data for INF904 in HS and CSU trials.

InflaRx surged 86.99% in premarket trading following the release of positive Phase 2a clinical trial results for its oral C5aR inhibitor INF904 in treating hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). The data demonstrated rapid, dose-dependent reductions in lesion counts, significant pain relief, and robust HiSCR responses in HS patients, while CSU patients showed substantial UAS7 score reductions, particularly in severe cases. INF904’s favorable safety profile, with no serious adverse events reported, further bolstered its potential as a best-in-class therapy. The company highlighted INF904’s pipeline-in-a-product versatility and plans to initiate Phase 2b trials in HS by 2026, aligning with its $1 billion addressable market projections. These developments, coupled with active discussions for collaborations, drove immediate investor optimism, reflected in the stock’s sharp premarket gains.